ESMO 2025 | Challenges in integrating oncolytic virotherapy into clinical practice
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the challenges of integrating oncolytic virotherapy into standard clinical practice, highlighting the need to standardize treatment and the potential of combining oncolytic viruses with other therapies, such as checkpoint inhibitors, to enhance local treatment for various metastases. Dr Kato notes that tailoring treatment to individual patients is a key issue, given the unique characteristics of each patient’s oncologic pattern. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Of course, there are some restrictions and the treatment of the oncologic patterns. For example, the abortion of the viral and so we can make a special treatment for each patient. That is one of the issues to standardize oncolytic viral treatment. But to enhance the local therapy, there is some potential of the oncolytic virus. For example, combined with checkpoint inhibitor or combined with another modality of the locus, for example, the liver metastasis or another, so, different metastasis...
Of course, there are some restrictions and the treatment of the oncologic patterns. For example, the abortion of the viral and so we can make a special treatment for each patient. That is one of the issues to standardize oncolytic viral treatment. But to enhance the local therapy, there is some potential of the oncolytic virus. For example, combined with checkpoint inhibitor or combined with another modality of the locus, for example, the liver metastasis or another, so, different metastasis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
